ADPT
ADPT clinical trials: Adaptive Biotechnologies Corp
Every trial on ClinicalTrials.gov where Adaptive Biotechnologies Corp is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 14
- Trials linked
- 8
- As lead sponsor
- 6
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ADPT on the catalyst calendar · ADPT registry changes
- Primary completion Sep 1, 2025Sponsor estimateNo phase registeredNCT05255354Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR TherapyAdaptive Biotechnologies · Follicular LymphomaRecruitingADPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 1, 2023ActualNo phase registeredNCT04545333The clonoSEQ® Watch RegistryAdaptive Biotechnologies · Acute Lymphoblastic Leukemia, Adult B-CellTerminatedADPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 14, 2023ActualNo phase registeredNCT05769829ImmuneSense™ IBD StudyAdaptive Biotechnologies · Inflammatory Bowel DiseasesTerminatedADPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 17, 2023ActualNo phase registeredNCT05112874ImmuneSense™ COVID-19 Cross-Reactivity StudyAdaptive Biotechnologies · Coronavirus DiseaseWithdrawnADPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 20, 2022ActualNo phase registeredNCT05054088ImmuneSense COVID-19 Variant StudyAdaptive Biotechnologies · Covid19CompletedADPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 4, 2020ActualNo phase registeredNCT04583982ImmuneSense™ COVID-19 StudyAdaptive Biotechnologies · Coronavirus Disease (COVID-19)CompletedADPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 29, 2021ActualNo phase registeredNCT04422314ImmuneSense Lyme StudyAdaptive Biotechnologies · Lyme DiseaseCompletedADPTLeadIQVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 23, 2021ActualNo phase registeredNCT04494893ImmuneRACE - Immune Response Action to COVID-19 EventsAdaptive Biotechnologies · Covid19CompletedADPTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2028Sponsor estimatePhase 2NCT06252675Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell LymphomaUniversity of California, San Francisco · Mantle Cell LymphomaRecruitingADPTCollaboratorLLYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2027Sponsor estimatePhase 2NCT04419519Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated...Memorial Sloan Kettering Cancer Center · Chronic Lymphocytic Leukemia (CLL)Active, not recruitingADPTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 4, 2025ActualNo phase registeredNCT05271630Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell TransplantH. Lee Moffitt Cancer Center and Research Institute · Multiple MyelomaActive, not recruitingADPTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 1, 2029Sponsor estimatePhase 2NCT06828991A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have...Danielle Wallace · Diffuse Large B-Cell Lymphoma (DLBCL)RecruitingADPTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 29, 2024ActualPhase 2NCT02553642Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated...Memorial Sloan Kettering Cancer Center · Bladder CancerCompletedADPTCollaboratorBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 29, 2027Sponsor estimatePhase 2NCT06557330MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin LymphomaFox Chase Cancer Center · LymphomaNot yet recruitingADPTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 14 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner